Business

Vectura and Mundipharma have signed an agreement for the development and commercialization of the VR2076 ICS/LABA/LAMA MDI, Vectura has announced. Skyepharma, which was acquired by Vectura earlier this year, had previously announced a development and commercialization deal for the MDI, then known as SKP-2076, in December 2015. Mundipharma and a "US associated … [Read more...] about Vectura and Mundipharma sign development deal for triple therapy MDI

Horizon Pharma has announced that Quinsair levofloxacin inhalation solution is now available in Canada for the treatment of P. aeruginosa lung infections in adult cystic fibrosis patients. Horizon acquired Quinsair when it acquired Raptor Pharmaceutical company in October 2016. Raptor launched Quinsair in Europe in April 2016. Horizon Pharma VP and General Manager, … [Read more...] about Horizon launches Quinsair inhaled levofloxacin in Canada

Sunovion has acquired exclusive US marketing rights to three Novartis DPIs for the treatment of COPD, the company has announced. The company said that it plans to market the Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler, and Arcapta (indacaterol) Neohaler beginning in 2017. Novartis will continue to manufacture the three … [Read more...] about Sunovion gets US rights to Utibron, Seebri, and Arcapta Neohalers

Cephalgia, a startup spun out of the University of Chicago, will receive $250,000 from the university's Innovation Fund for development of intranasal IGF-1 for the treatment of migraine, according to the fund. The company was selected to receive the money after pitching its business plan in a live competition. University of Chicago Associate VP for Entrepreneurship … [Read more...] about Startup Cephalgia gets funding from University of Chicago Innovation Fund for intranasal IGF-1

Intranasal drug developer Impel NeuroPharma has received $21 million in the initial tranche of a Series C financing round, with another $15 million available on completion of development and business milestones, the company said. Investors venBIO, 5AM Ventures and Vivo Capital, contributed equally. Impel NeuroPharma CEO John Hoekman said, “The nasal cavity is a … [Read more...] about Impel NeuroPharma raises $36 million for development of intranasal CNS products

Teva Israel and Syqe Medical have announced that Teva will distribute Syqe's cannabis inhaler in Israel, with Syqe responsible for manufacturing the inhaler and cartridges. No financial terms were disclosed. The Syqe device delivers 100 mcg doses using heat and controlled air flow plus cartridges filled with "structurally modified" raw plants. According to Teva, … [Read more...] about Teva to market Syqe cannabis inhaler in Israel

On November 14, 2016, Judge Sue Robinson of the US District Court for the District of Delaware issued a ruling upholding Merck's US patent 6,127,353 but finding that Teva's mometasone nasal spray ANDA does not infringe the claims of that patent. Merck filed suit against Teva in July 2014 after Teva submitted an ANDA for the product to the FDA. Much of the … [Read more...] about US federal judge rules that Teva’s mometasone furoate nasal spray does not infringe on Merck’s patent

Pharmaxis will collaborate with the Woolcock Institute of Medical Research to develop a tobramycin dry powder inhaler for the treatment of cystic fibrosis, the company has announced. A A$421,545 grant from the Australian National Health and Medical Research Council (NHMRC) will fund the research to develop a dry powder formulation for delivery by Pharmaxis's Orbital … [Read more...] about Pharmaxis partners with Woolcock Institute on development of tobramycin DPI

According to MannKind Corporation, it has reached an agreement with Sanofi regarding the return of rights to Afrezza inhaled insulin, in which "All issues arising out of the license and collaboration agreement, the supply agreement, the promissory note, the security agreement and the transition agreement are resolved." In January 2016, Sanofi announced that it … [Read more...] about Sanofi and MannKind finalize agreement on return of Afrezza rights